3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
9
Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Obesity
3
Breast Neoplasms
3
Brain Neoplasms
3
Sarcopenia
2
Multiple Myeloma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Renal Insufficiency, Chronic
1
Rehabilitation Exercise
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphedema
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
34
Doxorubicin
24
fludarabine phosphate
20
Vinblastine
20
Nivolumab
20
Dacarbazine
20
Brentuximab Vedotin
20
pembrolizumab
19
fludarabine
18
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
14
Filgrastim
13
Melphalan
12
Granulocyte Colony-Stimulating Factor
10
Gemcitabine
10
Bleomycin
10
Tacrolimus
9
Radiotherapy
9
Prednisone
9
Peripheral Blood Stem Cell Transplantation
9
Busulfan
9
Specimen Handling
8
Vincristine
7
Sirolimus
7
Magnetic Resonance Spectroscopy
7
Cyclosporine
7
pegfilgrastim
6
Stem Cell Transplantation
6
Bendamustine Hydrochloride
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
Resistance Training
×
1 year
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled